Medidata Solutions, Inc. (NASDAQ:MDSO) had its price objective raised by analysts at Morgan Stanley from $74.00 to $86.00 in a research report issued to clients and investors on Thursday, July 20th. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 10.55% from the company’s previous close.
A number of other research analysts have also recently issued reports on MDSO. Zacks Investment Research raised shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, May 3rd. Citigroup Inc. reaffirmed a “buy” rating and set a $94.00 target price (up previously from $77.00) on shares of Medidata Solutions in a research note on Monday, July 10th. Piper Jaffray Companies boosted their target price on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research note on Friday, July 7th. BidaskClub cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Finally, KeyCorp boosted their target price on shares of Medidata Solutions from $71.00 to $74.00 and gave the stock an “overweight” rating in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $78.17.
Shares of Medidata Solutions (NASDAQ:MDSO) opened at 77.79 on Thursday. Medidata Solutions has a 1-year low of $46.10 and a 1-year high of $85.92. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of 125.67 and a beta of 1.79. The stock has a 50 day moving average price of $78.22 and a 200-day moving average price of $66.06.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $137.41 million for the quarter, compared to analysts’ expectations of $134.28 million. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period last year, the firm posted $0.24 earnings per share. On average, equities research analysts expect that Medidata Solutions will post $1.28 earnings per share for the current fiscal year.
In other news, Director Robert Taylor sold 5,639 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $73.46, for a total transaction of $414,240.94. Following the completion of the sale, the director now directly owns 54,372 shares of the company’s stock, valued at $3,994,167.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $69.46, for a total transaction of $347,300.00. Following the sale, the chief operating officer now directly owns 171,754 shares of the company’s stock, valued at $11,930,032.84. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.
Large investors have recently modified their holdings of the company. Brown Capital Management LLC increased its stake in shares of Medidata Solutions by 0.6% in the first quarter. Brown Capital Management LLC now owns 5,921,818 shares of the company’s stock worth $341,630,000 after buying an additional 33,042 shares during the last quarter. Vanguard Group Inc. boosted its stake in Medidata Solutions by 5.1% in the first quarter. Vanguard Group Inc. now owns 4,874,974 shares of the company’s stock valued at $281,237,000 after buying an additional 235,190 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Medidata Solutions by 61.4% in the first quarter. Clearbridge Investments LLC now owns 2,449,038 shares of the company’s stock valued at $141,285,000 after buying an additional 931,729 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in Medidata Solutions by 11.5% in the first quarter. Champlain Investment Partners LLC now owns 1,653,230 shares of the company’s stock valued at $95,375,000 after buying an additional 169,870 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Medidata Solutions by 17.1% in the first quarter. State Street Corp now owns 1,432,120 shares of the company’s stock worth $82,615,000 after buying an additional 209,074 shares during the period.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.